Fenwick & West LLP advises a client base consisting of emerging companies and internationally established businesses active in immuno-oncology, diagnostics and digital health, among a multitude of other areas. The practice assists clients with a range of issues, including patent and Hatch-Waxman disputes, due diligence in the lead up to acquisitions and financings in the life sciences industry, and issuer-side IPOs. Leadership of the team is shared between San Francisco-based Matthew Rossiter, who advises on corporate structuring and IP protection strategies, Seattle’s Melanie Mayer, a specialist in patent and licensing disputes, and Stefano Quintini, based in Silicon Valley and overseeing collaboration agreements and joint ventures. New York-based Carl Morales is well versed in developing patent portfolios for clients with FDA-approved drugs.
Testimonials
Collated independently by Legal 500 research team.
‘Carl Morales is a knowledgeable, commercial, responsive and thoughtful partner who we reach out to for our IP questions/concerns. Great partner to collaborate with on our transactions.’
Key clients
- Amyndas Pharmaceuticals
- Chinook Therapeutics, Inc.
Work highlights
- Represented Novo Nordisk in Hatch-Waxman litigation to protect its most high-profile products, including Ozempic.
- Represented Chinook Therapeutics, Inc. in its acquisition by Novartis for $3.5bn.